PRQR
ProQR Therapeutics N.V. [PRQR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PRQR Stock Summary
Top 10 Correlated ETFs
PRQR
Top 10 Correlated Stocks
PRQR
In the News
PRQR Financial details
Company Rating
Neutral
Market Cap
177.8M
Income
-27.04M
Revenue
6.43M
Book val./share
0.53
Cash/share
1.52
Dividend
-
Dividend %
-
Employees
156
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-4.53
Forward P/E
-
PEG
0.72
P/S
36.07
P/B
3.16
P/C
1.22
P/FCF
17.65
Quick Ratio
4.64
Current Ratio
4.68
Debt / Equity
0.14
LT Debt / Equity
0.1
-
-
EPS (TTM)
-0.34
EPS next Y
-
EPS next Q
-
EPS this Y
-62.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.44%
Revenue last 5Y
26.98%
Revenue Q/Q
133.56%
EPS Q/Q
-3.4%
-
-
-
-
SMA20
-9.79%
SMA50
-0.47%
SMA100
46.21%
Inst Own
16.38%
Inst Trans
0.63%
ROA
-23%
ROE
-58%
ROC
-0.33%
Gross Margin
100%
Oper. Margin
-937%
Profit Margin
-798%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.11-3.29
52W High
-38%
52W Low
+86%
RSI
35.64
Rel Volume
0.37
Avg Volume
309.7K
Volume
114.66K
Perf Week
-22.18%
Perf Month
-1.59%
Perf Quarter
55%
Perf Half Y
43.08%
-
-
-
-
Beta
0.246
-
-
Volatility
0.16%, 0.18%
Prev Close
-2.11%
Price
1.86
Change
-7%
PRQR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0 | 0.02 | 0.06 | 0.08 | |
| Net income per share | -1.38 | -0.93 | -0.96 | -0.91 | -0.34 | |
| Operating cash flow per share | -1.07 | -0.94 | -0.41 | -0.96 | 0.26 | |
| Free cash flow per share | -1.09 | -0.96 | -0.41 | -0.97 | 0.22 | |
| Cash per share | 2.73 | 1.51 | 2.92 | 1.32 | 1.47 | |
| Book value per share | 2.3 | 1.14 | 1.77 | 0.91 | 0.51 | |
| Tangible book value per share | 2.29 | 1.13 | 1.76 | 0.91 | 0.51 | |
| Share holders equity per share | 2.3 | 1.14 | 1.77 | 0.91 | 0.51 | |
| Interest debt per share | 0.36 | 0.73 | 0.99 | 0.38 | 0.09 | |
| Market cap | 361.33M | 171.99M | 453.95M | 248.45M | 145.12M | |
| Enterprise value | 262.94M | 130.43M | 326.8M | 175.65M | 45.84M | |
| P/E ratio | -6.37 | -3.69 | -7.36 | -3.83 | -5.27 | |
| Price to sales ratio | 186.93 | 0 | 335.27 | 61.54 | 22.74 | |
| POCF ratio | -8.22 | -3.65 | -17.45 | -3.63 | 6.88 | |
| PFCF ratio | -8.11 | -3.58 | -17.13 | -3.59 | 8.31 | |
| P/B Ratio | 3.83 | 3.01 | 3.99 | 3.79 | 3.5 | |
| PTB ratio | 3.83 | 3.01 | 3.99 | 3.79 | 3.5 | |
| EV to sales | 136.03 | 0 | 241.36 | 43.51 | 7.18 | |
| Enterprise value over EBITDA | -4.59 | -2.64 | -5.9 | -2.96 | -1.45 | |
| EV to operating cash flow | -5.98 | -2.77 | -12.56 | -2.56 | 2.17 | |
| EV to free cash flow | -5.9 | -2.72 | -12.33 | -2.54 | 2.63 | |
| Earnings yield | -0.16 | -0.27 | -0.14 | -0.26 | -0.19 | |
| Free cash flow yield | -0.12 | -0.28 | -0.06 | -0.28 | 0.12 | |
| Debt to equity | 0.14 | 0.6 | 0.53 | 0.34 | 0.14 | |
| Debt to assets | 0.12 | 0.35 | 0.29 | 0.13 | 0.04 | |
| Net debt to EBITDA | 1.72 | 0.84 | 2.3 | 1.23 | 3.13 | |
| Current ratio | 10.43 | 7.77 | 6.94 | 7.32 | 3.54 | |
| Interest coverage | -53.04 | -20.77 | -16.8 | -12.62 | -29.75 | |
| Income quality | 0.77 | 1.01 | 0.42 | 1.06 | -0.77 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.67 | 0 | 12.83 | 4.62 | 2.54 | |
| Research and developement to revenue | 24.05 | 0 | 31.18 | 12.6 | 3.55 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0.02 | 0.01 | -0.17 | |
| Capex to revenue | -0.3 | 0 | -0.36 | -0.18 | -0.57 | |
| Capex to depreciation | -0.28 | -0.39 | -0.21 | -0.28 | -1.48 | |
| Stock based compensation to revenue | 4.71 | 0 | 4.59 | 0.71 | 0.49 | |
| Graham number | 8.46 | 4.89 | 6.19 | 4.32 | 1.98 | |
| ROIC | -0.53 | -0.39 | -0.3 | -0.63 | -0.56 | |
| Return on tangible assets | -0.48 | -0.47 | -0.29 | -0.38 | -0.2 | |
| Graham Net | 2.17 | 0.68 | 1.43 | 0.44 | 0.29 | |
| Working capital | 103.67M | 69.72M | 163.89M | 133.35M | 86.85M | |
| Tangible asset value | 93.83M | 56.55M | 113.23M | 65.11M | 41.42M | |
| Net current asset value | 90.96M | 37.84M | 95.13M | 48.25M | 24.51M | |
| Invested capital | 0.14 | 0.6 | 0.53 | 0.34 | 0.14 | |
| Average receivables | 1.05M | 635.5K | 488K | 28.9M | 29.25M | |
| Average payables | 290K | 333K | 206K | 291.5K | 967.14K | |
| Average inventory | 619.5K | 359.5K | 322.73K | 136.66K | 3.43K | |
| Days sales outstanding | 160.5 | 0 | 149.61 | 5.17K | 72.6 | |
| Days payables outstanding | 1.39 | 36.76 | 0 | 57.8 | 0 | |
| Days of inventory on hand | 1.06 | 63.05 | 0 | 1.01 | 0 | |
| Receivables turnover | 2.27 | 0 | 2.44 | 0.07 | 5.03 | |
| Payables turnover | 262.52 | 9.93 | 0 | 6.32 | 0 | |
| Inventory turnover | 343.6 | 5.79 | 0 | 360.61 | 0 | |
| ROE | -0.6 | -0.82 | -0.54 | -0.99 | -0.66 | |
| Capex per share | -0.01 | -0.02 | -0.01 | -0.01 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | |
| Net income per share | -0.14 | -0.1 | -0.1 | -0.07 | -0.07 | |
| Operating cash flow per share | -0.23 | 0.55 | -0.13 | -0.09 | -0.07 | |
| Free cash flow per share | -0.23 | 0.55 | -0.13 | -0.1 | -0.11 | |
| Cash per share | 1.22 | 1.72 | 1.59 | 1.49 | 1.52 | |
| Book value per share | 0.85 | 0.73 | 0.64 | 0.57 | 0.53 | |
| Tangible book value per share | 0.84 | 0.73 | 0.64 | 0.57 | 0.53 | |
| Share holders equity per share | 0.85 | 0.73 | 0.64 | 0.57 | 0.53 | |
| Interest debt per share | 0.27 | 0.26 | 0.27 | 0.26 | 0.08 | |
| Market cap | 268.38M | 172.29M | 120.65M | 100.47M | 140.55M | |
| Enterprise value | 195.58M | 54.72M | 13.62M | 1.19M | 41.27M | |
| P/E ratio | -6.31 | -5.39 | -3.77 | -4.4 | -6.58 | |
| Price to sales ratio | 326.5 | 263.04 | 100.12 | 73.33 | 43.92 | |
| POCF ratio | -15.05 | 3.85 | -11.66 | -13.38 | -25.61 | |
| PFCF ratio | -15.06 | 3.86 | -11.34 | -12.8 | -16.82 | |
| P/B Ratio | 4.1 | 2.92 | 2.33 | 2.17 | 3.39 | |
| PTB ratio | 4.1 | 2.92 | 2.33 | 2.17 | 3.39 | |
| EV to sales | 237.93 | 83.55 | 11.3 | 0.87 | 12.9 | |
| Enterprise value over EBITDA | -17.16 | -5.92 | -1.63 | -0.14 | -5 | |
| EV to operating cash flow | -10.97 | 1.22 | -1.32 | -0.16 | -7.52 | |
| EV to free cash flow | -10.98 | 1.23 | -1.28 | -0.15 | -4.94 | |
| Earnings yield | -0.04 | -0.05 | -0.07 | -0.06 | -0.04 | |
| Free cash flow yield | -0.07 | 0.26 | -0.09 | -0.08 | -0.06 | |
| Debt to equity | 0.34 | 0.36 | 0.42 | 0.46 | 0.14 | |
| Debt to assets | 0.13 | 0.14 | 0.15 | 0.15 | 0.04 | |
| Net debt to EBITDA | 6.39 | 12.71 | 12.81 | 12.11 | 12.03 | |
| Current ratio | 7.32 | 8.25 | 5.71 | 4.68 | 3.54 | |
| Interest coverage | 12.77 | 17.58 | 0 | 0 | 0 | |
| Income quality | 1.57 | -5.05 | 1.3 | 1.39 | 1.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.62 | 6.15 | 3.44 | 2.42 | 1.48 | |
| Research and developement to revenue | 13.02 | 9.25 | 4.9 | 3.98 | 2.35 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.03 | 0.05 | 0.52 | |
| Capex to revenue | 0.02 | -0.21 | -0.24 | -0.25 | -0.9 | |
| Capex to depreciation | 0.02 | -0.25 | -0.49 | -0.53 | -4.04 | |
| Stock based compensation to revenue | -0.47 | 1.67 | 0.63 | 0.32 | 0.25 | |
| Graham number | 1.62 | 1.27 | 1.19 | 0.95 | 0.9 | |
| ROIC | -0.11 | -0.09 | -0.1 | -0.09 | -0.15 | |
| Return on tangible assets | -0.06 | -0.05 | -0.05 | -0.04 | -0.04 | |
| Graham Net | 0.41 | 0.49 | 0.4 | 0.34 | 0.3 | |
| Working capital | 133.35M | 124.45M | 108.17M | 98.04M | 86.85M | |
| Tangible asset value | 65.11M | 58.7M | 51.5M | 46.34M | 41.42M | |
| Net current asset value | 48.25M | 42.3M | 34.66M | 28.99M | 24.51M | |
| Invested capital | 0.34 | 0.36 | 0.42 | 0.46 | 0.14 | |
| Average receivables | 28.9M | 28.85M | 428.5K | 1.78M | 2.22M | |
| Average payables | 408.5K | 334K | 197.5K | 118K | 829.64K | |
| Average inventory | 3.43K | 792.5 | -2.9K | -1.02K | -761 | |
| Days sales outstanding | 6.27K | 62.79 | 29.88 | 207.92 | 35.69 | |
| Days payables outstanding | 49.49 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0.87 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 1.43 | 3.01 | 0.43 | 2.52 | |
| Payables turnover | 1.82 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 103.85 | 0 | 0 | 0 | 0 | |
| ROE | -0.16 | -0.14 | -0.15 | -0.12 | -0.13 | |
| Capex per share | 0 | 0 | 0 | 0 | -0.04 |
PRQR Frequently Asked Questions
What is ProQR Therapeutics N.V. stock symbol ?
ProQR Therapeutics N.V. is a NL stock and trading under the symbol PRQR
What is ProQR Therapeutics N.V. stock quote today ?
ProQR Therapeutics N.V. stock price is $1.86 today.
Is ProQR Therapeutics N.V. stock public?
Yes, ProQR Therapeutics N.V. is a publicly traded company.
Company Profile
- Volume Average 309.7K
- Market Capitalization 177.8M
- Employee 156
- CEO Mr. Daniel Anton de Boer
- Headquarters Leiden,NL
- IPO Date 2014-09-18
-
Website
https://www.proqr.com 
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
